These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 19049435)

  • 1. The pharmacokinetic-pharmacodynamic modelling framework as a tool to predict drug resistance evolution.
    Witzany C; Rolff J; Regoes RR; Igler C
    Microbiology (Reading); 2023 Jul; 169(7):. PubMed ID: 37522891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PK/PD Analysis by Nonlinear Mixed-Effects Modeling of a Marbofloxacin Dose Regimen for Treatment of Goat Mastitis Produced by Coagulase-Negative Staphylococci.
    Lorenzutti AM; Vico JP; Serrano-Rodríguez JM; Himelfarb MA; Andrés-Larrea MIS; Lucas-Burneo JJ; Litterio NJ
    Animals (Basel); 2021 Oct; 11(11):. PubMed ID: 34827830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling of Effective Antimicrobials to Reduce
    Shukla SK; Carter TC; Ye Z; Pantrangi M; Rose WE
    Toxins (Basel); 2020 Jan; 12(2):. PubMed ID: 31979087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generating Robust and Informative Nonclinical
    Bulitta JB; Hope WW; Eakin AE; Guina T; Tam VH; Louie A; Drusano GL; Hoover JL
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolutionary epidemiology models to predict the dynamics of antibiotic resistance.
    Blanquart F
    Evol Appl; 2019 Mar; 12(3):365-383. PubMed ID: 30828361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling.
    Jacobs M; Grégoire N; Couet W; Bulitta JB
    PLoS Comput Biol; 2016 Mar; 12(3):e1004782. PubMed ID: 26967893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.
    Drusano GL; Louie A; MacGowan A; Hope W
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1183-93. PubMed ID: 26711759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
    Ly NS; Bulitta JB; Rao GG; Landersdorfer CB; Holden PN; Forrest A; Bergen PJ; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2015 May; 70(5):1434-42. PubMed ID: 25712313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease.
    Rao GG; Ly NS; Haas CE; Garonzik S; Forrest A; Bulitta JB; Kelchlin PA; Holden PN; Nation RL; Li J; Tsuji BT
    Antimicrob Agents Chemother; 2014; 58(3):1381-8. PubMed ID: 24342636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggressive chemotherapy and the selection of drug resistant pathogens.
    Huijben S; Bell AS; Sim DG; Tomasello D; Mideo N; Day T; Read AF
    PLoS Pathog; 2013 Sep; 9(9):e1003578. PubMed ID: 24068922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbidity in Atopic Dermatitis.
    Simpson EL
    Curr Dermatol Rep; 2012 Mar; 1(1):29-38. PubMed ID: 23745171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.
    Martinez MN; Papich MG; Drusano GL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2795-805. PubMed ID: 22371890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.
    Rice LB
    Mayo Clin Proc; 2012 Feb; 87(2):198-208. PubMed ID: 22305032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant Staphylococcus aureus strain MW2.
    Pichereau S; Pantrangi M; Couet W; Badiou C; Lina G; Shukla SK; Rose WE
    Antimicrob Agents Chemother; 2012 Jan; 56(1):140-7. PubMed ID: 22064533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy, within-host ecology and the fitness of drug-resistant malaria parasites.
    Huijben S; Nelson WA; Wargo AR; Sim DG; Drew DR; Read AF
    Evolution; 2010 Oct; 64(10):2952-68. PubMed ID: 20584075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro synergism of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotypes Paratyphi A and Paratyphi B.
    Neupane GP; Kim DM; Kim SH; Lee BK
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3696-701. PubMed ID: 20566759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
    Louie A; Bied A; Fregeau C; Van Scoy B; Brown D; Liu W; Bush K; Queenan AM; Morrow B; Khashab M; Kahn JB; Nicholson S; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2638-45. PubMed ID: 20308371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
    Vidaillac C; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus.
    Drusano GL; Liu W; Brown DL; Rice LB; Louie A
    J Infect Dis; 2009 Jan; 199(2):219-26. PubMed ID: 19049435
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.